{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:33:51Z","timestamp":1793885631772,"version":"4.8.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.esmoop.2023.101600","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:05:11Z","timestamp":1689206711000},"page":"101600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies"],"prefix":"10.1016","volume":"8","author":[{"given":"M.V.","family":"Dietz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"van Kooten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Paats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.V.J.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.V.E.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.","family":"Dubbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"von der Th\u00fcsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.esmoop.2023.101600_bib1","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1245\/s10434-019-07803-z","article-title":"Malignant peritoneal mesothelioma: patterns of care and survival in the Netherlands: a population-based study","volume":"26","author":"de Boer","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101600_bib2","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis","volume":"22","author":"Helm","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"36","key":"10.1016\/j.esmoop.2023.101600_bib3","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101600_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program","volume":"7","author":"J\u00e4nne","year":"2005","journal-title":"Clin Lung Cancer"},{"issue":"21","key":"10.1016\/j.esmoop.2023.101600_bib5","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1200\/JCO.2007.15.2868","article-title":"Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial","volume":"26","author":"Simon","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101600_bib6","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2023.101600_bib7","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101600_bib8","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1158\/1078-0432.CCR-21-3752","article-title":"Patients with rare cancers in the Drug Rediscovery Protocol (DRUP) benefit from genomics-guided treatment","volume":"28","author":"Hoes","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101600_bib9","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jtho.2016.05.020","article-title":"The genetic landscape of malignant pleural mesothelioma: results from massively parallel sequencing","volume":"11","author":"Hylebos","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101600_bib10","first-page":"402","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101600_bib11","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1080\/0284186X.2021.1955971","article-title":"Epidemiology and outcome of peritoneal and pleural mesothelioma subtypes in Norway. A 20 year nation-wide study","volume":"60","author":"Brustugun","year":"2021","journal-title":"Acta Oncologica"},{"key":"10.1016\/j.esmoop.2023.101600_bib12","article-title":"Molecular characterization of mesothelioma: impact of histologic type and site of origin on molecular landscape","volume":"6","author":"Dagogo-Jack","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101600_bib13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"7776","key":"10.1016\/j.esmoop.2023.101600_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-019-1600-x","article-title":"The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs","volume":"574","author":"van der Velden","year":"2019","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101600_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119689","article-title":"Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing","volume":"10","author":"Sheffield","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101600_bib20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12967-015-0485-1","article-title":"BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma","volume":"13","author":"Alakus","year":"2015","journal-title":"J\u00a0Transl Med"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101600_bib72","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1158\/1535-7163.MCT-16-0229","article-title":"Genomic landscape of malignant mesotheliomas","volume":"15","author":"Kato","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101600_bib73","first-page":"2331","article-title":"Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma","volume":"36","author":"Ugurluer","year":"2016","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101600_bib21","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/modpathol.2016.188","article-title":"Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X","volume":"30","author":"Joseph","year":"2017","journal-title":"Mod Pathol"},{"issue":"28","key":"10.1016\/j.esmoop.2023.101600_bib22","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101600_bib75","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.tranon.2018.01.005","article-title":"Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS","volume":"11","author":"Kim","year":"2018","journal-title":"Transl Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101600_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0620-3","article-title":"BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma","volume":"11","author":"Shrestha","year":"2019","journal-title":"Genome Med"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101600_bib77","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/s41379-020-0588-y","article-title":"Molecular characterization of diffuse malignant peritoneal mesothelioma","volume":"33","author":"Hung","year":"2020","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101600_bib78","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/1759-7714.13491","article-title":"Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma","volume":"11","author":"Taghizadeh","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.esmoop.2023.101600_bib17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jtho.2021.09.012","article-title":"Molecular characterization of peritoneal mesotheliomas","volume":"17","author":"Offin","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2023.101600_bib18","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101600_bib23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12935-022-02597-9","article-title":"DNA repair and damage pathways in mesothelioma development and therapy","volume":"22","author":"Malakoti","year":"2022","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.esmoop.2023.101600_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102091","article-title":"BAP1: not just a BRCA1-associated protein","volume":"90","author":"Louie","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101600_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/bfgp\/elm007","article-title":"Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease","volume":"6","author":"Angeloni","year":"2007","journal-title":"Brief Funct Genomics"},{"key":"10.1016\/j.esmoop.2023.101600_bib26","series-title":"GeneReviews\u00ae","article-title":"BAP1 tumor predisposition syndrome","author":"Pilarski","year":"1993"},{"key":"10.1016\/j.esmoop.2023.101600_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.dnarep.2019.03.007","article-title":"SWI\/SNF: complex complexes in genome stability and cancer","volume":"77","author":"Ribeiro-Silva","year":"2019","journal-title":"DNA Repair"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101600_bib28","first-page":"F115","article-title":"The p16INK4a\/CDKN2A tumor suppressor and its relatives","volume":"1378","author":"Ruas","year":"1998","journal-title":"Biochim Biophys Acta"},{"issue":"6531","key":"10.1016\/j.esmoop.2023.101600_bib29","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/375503a0","article-title":"Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16","volume":"375","author":"Lukas","year":"1995","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.esmoop.2023.101600_bib30","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1093\/emboj\/17.17.5001","article-title":"The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2","volume":"17","author":"Stott","year":"1998","journal-title":"EMBO J"},{"issue":"6494","key":"10.1016\/j.esmoop.2023.101600_bib31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/371257a0","article-title":"p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest","volume":"371","author":"Hannon","year":"1994","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101600_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","article-title":"Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others","volume":"15","author":"Sabapathy","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101600_bib33","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ccell.2017.04.013","article-title":"A\u00a0pan-cancer proteogenomic atlas of PI3K\/AKT\/mTOR pathway alterations","volume":"31","author":"Zhang","year":"2017","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.esmoop.2023.101600_bib34","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101600_bib35","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2174\/138920310791824011","article-title":"Merlin, a \u201cmagic\u201d linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival","volume":"11","author":"Stamenkovic","year":"2010","journal-title":"Curr Protein Pept Sci"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101600_bib36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101600_bib37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101600_bib38","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.thorsurg.2020.08.005","article-title":"The molecular basis of malignant pleural mesothelioma","volume":"30","author":"Wadowski","year":"2020","journal-title":"Thorac Surg Clin"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101600_bib39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101600_bib40","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jtho.2019.11.011","article-title":"Anaplastic lymphoma kinase gene rearrangement in children and young adults with mesothelioma","volume":"15","author":"Mian","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101600_bib41","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/j.jtho.2020.05.025","article-title":"ALK in mesothelioma: to FISH or not to FISH?","volume":"15","author":"Cornelissen","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2023.101600_bib42","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2020.05.019","article-title":"NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer","volume":"146","author":"Leal","year":"2020","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101600_bib43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.gene.2015.03.031","article-title":"Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma","volume":"563","author":"Sneddon","year":"2015","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101600_bib44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2014.10.017","article-title":"Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases","volume":"87","author":"Rusch","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2023.101600_bib45","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2021.12.023","article-title":"Malignant pleural mesothelioma: germline variants in DNA repair genes may steer tailored treatment","volume":"163","author":"Sculco","year":"2022","journal-title":"Eur J Cancer"},{"issue":"18","key":"10.1016\/j.esmoop.2023.101600_bib46","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"33","key":"10.1016\/j.esmoop.2023.101600_bib47","doi-asserted-by":"crossref","first-page":"182","DOI":"10.14694\/EdBook_AM.2013.33.182","article-title":"Peritoneal mesothelioma: the site of origin matters","author":"Kindler","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101600_bib48","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/annonc\/mdl345","article-title":"Epidemiology of peritoneal mesothelioma: a review","volume":"18","author":"Boffetta","year":"2007","journal-title":"Ann Oncol"},{"issue":"33","key":"10.1016\/j.esmoop.2023.101600_bib49","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1200\/JCO.19.03010","article-title":"Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)","volume":"38","author":"Keith","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101600_bib50","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101600_bib51","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1470-2045(22)00062-6","article-title":"Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial","volume":"23","author":"Fennell","year":"2022","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2023.101600_bib52","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101600_bib53","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101600_bib54","first-page":"100231","article-title":"Phase 2 study of olaparib in malignant mesothelioma and correlation of efficacy with germline or somatic mutations in BAP1 gene","volume":"2","author":"Ghafoor","year":"2021","journal-title":"JTO Clin Res Rep"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101600_bib55","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2023.101600_bib56","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101600_bib57","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1016\/S1470-2045(15)00077-7","article-title":"Genomic alterations in lung adenocarcinoma","volume":"16","author":"Devarakonda","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2023.101600_bib58","first-page":"17","article-title":"ALK inhibitors, a pharmaceutical perspective","volume":"2","author":"Galvani","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2023.101600_bib59","article-title":"Impact of ALK inhibitors in patients with ALK-rearranged nonlung solid tumors","volume":"5","author":"Takeyasu","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101600_bib60","first-page":"CD013453","article-title":"Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer","volume":"1","author":"Cameron","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101600_bib61","doi-asserted-by":"crossref","first-page":"djv253","DOI":"10.1093\/jnci\/djv253","article-title":"Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval","volume":"107","author":"Jardim","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"32","key":"10.1016\/j.esmoop.2023.101600_bib62","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","article-title":"Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials","volume":"33","author":"Schwaederle","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101600_bib63","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13073-022-01024-y","article-title":"A\u00a0mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals\u00a0the immune response landscape","volume":"14","author":"Long","year":"2022","journal-title":"Genome Med"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101600_bib64","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","article-title":"BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study","volume":"17","author":"Louw","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101600_bib65","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.101600_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.660039","article-title":"Tumor immune microenvironment and genetic alterations in mesothelioma","volume":"11","author":"Hiltbrunner","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2023.101600_bib67","article-title":"Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy","volume":"9","author":"Harber","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101600_bib68","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101600_bib69","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/0008-5472.CAN-15-0295","article-title":"Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer","volume":"76","author":"Ohar","year":"2016","journal-title":"Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923008359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923008359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:31:20Z","timestamp":1761856280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923008359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2059702923008359"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101600","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101600","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101600"}}